Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4N4W

Structure of the human smoothened receptor in complex with SANT-1.

Summary for 4N4W
Entry DOI10.2210/pdb4n4w/pdb
Related4JKV
DescriptorCytochrome b(562),Smoothened homolog, alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, (E)-N-(4-benzylpiperazin-1-yl)-1-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)methanimine, ... (8 entities in total)
Functional Keywordshuman smoothened receptor, antitumor agent, novel protein engineering, gpcr network, membrane protein, psi-biology, structural genomics, gpcr, membrane, transport protein
Biological sourceShigella flexneri 5 str. 8401
More
Total number of polymer chains1
Total formula weight55387.42
Authors
Wang, C.,Wu, H.,Han, G.W.,Cherezov, V.,Stevens, R.C.,GPCR Network (GPCR) (deposition date: 2013-10-08, release date: 2014-01-22, Last modification date: 2024-11-20)
Primary citationWang, C.,Wu, H.,Evron, T.,Vardy, E.,Han, G.W.,Huang, X.P.,Hufeisen, S.J.,Mangano, T.J.,Urban, D.J.,Katritch, V.,Cherezov, V.,Caron, M.G.,Roth, B.L.,Stevens, R.C.
Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs.
Nat Commun, 5:4355-4355, 2014
Cited by
PubMed Abstract: The Smoothened receptor (SMO) mediates signal transduction in the hedgehog pathway, which is implicated in normal development and carcinogenesis. SMO antagonists can suppress the growth of some tumours; however, mutations at SMO have been found to abolish their antitumour effects, a phenomenon known as chemoresistance. Here we report three crystal structures of human SMO bound to the antagonists SANT1 and Anta XV, and the agonist, SAG1.5, at 2.6-2.8 Å resolution. The long and narrow cavity in the transmembrane domain of SMO harbours multiple ligand binding sites, where SANT1 binds at a deeper site as compared with other ligands. Distinct interactions at D473(6.54f) elucidated the structural basis for the differential effects of chemoresistance mutations on SMO antagonists. The agonist SAG1.5 induces a conformational rearrangement of the binding pocket residues, which could contribute to SMO activation. Collectively, these studies reveal the structural basis for the modulation of SMO by small molecules.
PubMed: 25008467
DOI: 10.1038/ncomms5355
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.8 Å)
Structure validation

235458

PDB entries from 2025-04-30

PDB statisticsPDBj update infoContact PDBjnumon